At Oncquest, we have
one of the widest
test portfolios in the
diagnostic industry.
With time, we have
adapted ourselves to
the market trends and
customer requirements
to develop tests
based on the protocol
requirements.
As a company,
what are the
opportunities yet to
be tapped and what
are the challenges
that haven’t been
overcome yet.
We strive to increase
the reach and widen
our horizon to other
continents.
The major concern
is that the diagnostic
industry relies on the
continuous innovation
of new technology
but for that we are
dependent on foreign
equipment and other
kits. This increases the
Dr Ravi Gaur, COO, Oncquest Laboratories
BIOVOICENEWS.COM
27